Weatherly Asset Management L. P. Lowers Stake in Pfizer Inc. (NYSE:PFE)

Weatherly Asset Management L. P. reduced its position in Pfizer Inc. (NYSE:PFE) by 16.2% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 25,933 shares of the biopharmaceutical company’s stock after selling 5,014 shares during the period. Weatherly Asset Management L. P.’s holdings in Pfizer were worth $747,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Adage Capital Partners GP L.L.C. raised its position in Pfizer by 40.5% in the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after purchasing an additional 1,365,295 shares during the period. LifePlan Financial LLC acquired a new position in Pfizer during the 4th quarter valued at about $255,000. Brookstone Capital Management grew its stake in shares of Pfizer by 88.5% in the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after purchasing an additional 212,369 shares in the last quarter. ETF Store Inc. increased its stake in shares of Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock valued at $214,000 after acquiring an additional 727 shares during the period. Finally, KLCM Advisors Inc. boosted its stake in Pfizer by 75.0% during the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock valued at $5,004,000 after buying an additional 74,487 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Down 0.1 %

Shares of PFE stock traded down $0.03 on Wednesday, hitting $26.29. The company had a trading volume of 11,646,960 shares, compared to its average volume of 41,720,766. The stock’s 50-day moving average is $27.07 and its two-hundred day moving average is $28.52. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The firm has a market cap of $148.87 billion, a P/E ratio of 72.72, a P/E/G ratio of 1.18 and a beta of 0.61. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.37.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same quarter in the previous year, the company earned $1.14 EPS. The company’s revenue for the quarter was down 41.3% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on PFE. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday, April 15th. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a report on Thursday, January 4th. Eleven equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.